Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation
First Claim
1. An implantable neurostimulator-implemented method for managing tachyarrhythmic risk accompanying central sleep apnea through vagus nerve stimulation, comprising the steps of:
- providing an implantable neurostimulator comprising a pulse generator configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (simultaneously in both afferent and efferent directions) of action potentials within neuronal fibers comprising a patient'"'"'s cervical vagus nerve;
storing operating modes of the pulse generator in a recordable memory, comprising;
parametrically defining a maintenance dose of the electrical therapeutic stimulation tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses at an intensity that avoids acute physiological side effects and with an unchanging cycle not triggered by physiological markers; and
parametrically defining a boost dose of the electrical therapeutic stimulation tuned to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity than the maintenance dose;
therapeutically delivering the maintenance dose to the vagus nerve independent of cardiac cycle via a pulse generator comprised in the implantable neurostimulator through at least a pair of helical electrodes electrically coupled to the pulse generator via a nerve stimulation therapy lead; and
monitoring the patient'"'"'s physiological state via at least one sensor comprised in the implantable neurostimulator, and upon sensing a pattern indicative of Cheyne-Stokes respiration, delivering the boost dose to the vagus nerve via the pulse generator through the pair of helical electrodes.
7 Assignments
0 Petitions
Accused Products
Abstract
A patient suffering from congestive heart failure is at increased risk of cardiac arrhythmogenesis during sleep, particularly if experiencing central sleep apnea as a co-morbidity. Low intensity peripheral neurostimulation therapies that target imbalance of the autonomic nervous system have been shown to improve clinical outcomes. Thus, bi-directional autonomic regulation therapy is delivered to the cervical vagus nerve at an intensity that is insufficient to elicit pathological or acute physiological side effects and without the requirement of an enabling physiological feature or triggering physiological marker. The patient'"'"'s physiology is monitored to identify periods of sleep. In one embodiment, upon sensing a condition indicative of tachyarrhythmia following a period of bradycardia, as naturally occurs during sleep, an enhanced “boost” dose of bi-directional neural stimulation intended to “break” the tachyarrhythmic condition is delivered. In a further embodiment, the boost dose is delivered upon sensing a physiological pattern indicative of Cheyne-Stokes respiration.
240 Citations
8 Claims
-
1. An implantable neurostimulator-implemented method for managing tachyarrhythmic risk accompanying central sleep apnea through vagus nerve stimulation, comprising the steps of:
-
providing an implantable neurostimulator comprising a pulse generator configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (simultaneously in both afferent and efferent directions) of action potentials within neuronal fibers comprising a patient'"'"'s cervical vagus nerve; storing operating modes of the pulse generator in a recordable memory, comprising; parametrically defining a maintenance dose of the electrical therapeutic stimulation tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses at an intensity that avoids acute physiological side effects and with an unchanging cycle not triggered by physiological markers; and parametrically defining a boost dose of the electrical therapeutic stimulation tuned to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity than the maintenance dose; therapeutically delivering the maintenance dose to the vagus nerve independent of cardiac cycle via a pulse generator comprised in the implantable neurostimulator through at least a pair of helical electrodes electrically coupled to the pulse generator via a nerve stimulation therapy lead; and monitoring the patient'"'"'s physiological state via at least one sensor comprised in the implantable neurostimulator, and upon sensing a pattern indicative of Cheyne-Stokes respiration, delivering the boost dose to the vagus nerve via the pulse generator through the pair of helical electrodes. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. An implantable neurostimulator-implemented apparatus for managing tachyarrhythmic risk accompanying central sleep apnea through vagus nerve stimulation, comprising the steps of:
-
means for providing an implantable neurostimulator comprising a pulse generator configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (simultaneously in both afferent and efferent directions) of action potentials within neuronal fibers comprising a patient'"'"'s cervical vagus nerve; means for storing operating modes of the pulse generator in a recordable memory, comprising; means for parametrically defining a maintenance dose of the electrical therapeutic stimulation tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses at an intensity that avoids acute physiological side effects and with an unchanging cycle not triggered by physiological markers; and means for parametrically defining a boost dose of the electrical therapeutic stimulation tuned to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity than the maintenance dose; means for therapeutically delivering the maintenance dose to the vagus nerve independent of cardiac cycle via a pulse generator comprised in the implantable neurostimulator through at least a pair of helical electrodes electrically coupled to the pulse generator via a nerve stimulation therapy lead; and means for monitoring the patient'"'"'s physiological state via at least one sensor comprised in the implantable neurostimulator, and upon sensing a pattern indicative of Cheyne-Stokes respiration, delivering the boost dose to the vagus nerve via the pulse generator through the pair of helical electrodes.
-
Specification